Evaluation of glucose uptake by skeletal muscle tissue and subcutaneous fat in HIV-infected patients with and without lipodystrophy using FDG-PET

Nuclear Medicine Communications

Volumn 31, Issue 4, 2010, Pages 311-314

  Sathekge, Mike ^a   Maes, Alex ^d,e   Kgomo, Mbo ^c   Stolz, Anton ^b   Ankrah, Alfred ^a   Van De Wiele, Christophe ^f  

^a STEVE BIKO ACADEMIC HOSPITAL   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c Louis Pasteur Medical Centre   (South Africa)

^d University Hospital Leuven ^*  (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

18F fluorodeoxyglucose positron emission tomography; Highly active antiretroviral therapy; Lipodystrophy

Indexed keywords

DIDANOSINE; EFAVIRENZ; FLUORODEOXYGLUCOSE F 18; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIAGNOSTIC AGENT; GLUCOSE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GLUCOSE TRANSPORT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE DIAGNOSIS; SKELETAL MUSCLE; SUBCUTANEOUS FAT; VIRUS LOAD; ADOLESCENT; CLINICAL TRIAL; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECT; FEMALE; INSULIN RESISTANCE; LIPODYSTROPHY; MALE; METABOLISM; MIDDLE AGED; SCINTISCANNING; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HIV INFECTIONS; HUMANS; INSULIN RESISTANCE; LIPODYSTROPHY; MALE; MIDDLE AGED; MUSCLE, SKELETAL; POSITRON-EMISSION TOMOGRAPHY; SUBCUTANEOUS FAT; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954507345     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e3283359058     Document Type: Article

References (22)

1. Carr A. Diagnosis, prediction and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidemaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-2099.
2. Behrens G, Stoll M, Schmidt R. Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 2000;23:57-76.
3. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;352:1881-1883. (Pubitemid 28279721)
4. Wohl D, Brown T. Management of morphologic changes associated with antiretroviral use in HIV-infected patients. J Acquir Immune Defic Syndr 2008;49: S93-S100.
5. Domingo P, Matias-Guiu X, Pujol R, Francia E, Lagarda E, Sambeat MA, Vazquez G. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitorassociated lipodystrophy. AIDS 1999;13:2261-2267.
6. Haberkorn U, Bellemann M, Brix G, Kamencic H, Morr I, Traut U, et al. Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine. Eur J Nucl Med Mol Imaging 2001;28:418-425.
7. Furuta M, Hasegawa M, Hayakawa K, Yamakawa M, Ishikawa H, Nonaka T, et al. Rapid rise in FDG uptake in an irradiated human tumor. J Nucl Med 1997;4:435-438.
8. Dubé M, Edmondson-Melançon H, Qian D, Aqeel R, Johnson D, Buchanan TA. Prospective evaluation of the effect of initiating indinavirbased therapy on insulin sensitivity and B-cell function in HIV-infected patients. J Acquire Immune Defic Syndr 2001;27:130-134.
9. Noor M, Lo J, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001;15: F11-F18.
10. Noor M, Seneviratne T, Aweeka F, Lo JC, Schwarz JM, Mulligan K, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002;16: F1-F6.
11. Nolte L, Yarakesheski K, Kawanaka K, Fisher J, Lo N, Holloszy JO. The HIV protease inhibitor indinavir decreases insulin-and concentration stimulated glucose transport in skeletal muscle. Diabetes 2001;50:1397-1401.
12. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs adipocyte differentiation and induces insulin resistance by probably altering ADD1/SREBP-1 maturation. Antivir Ther 2000;3:4.
13. Fessel W, Follansbee S, Barker B. Ultrastructural findings consistent with brown adipocytes in buffalo humps of HIV-positive patients with fat redistribution syndrome. Antivir Ther 2000;3:5. (abstract P1).
14. Zhang B, MacNaul K, Szalkowski D, Li Z, Berger J, Moller D. Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab 1999;84:4274-4277.
15. Basu S, Alavi A. Optimizing interventions for preventing uptake in the brown adipose tissue in FDG PET. Eur J Nucl Med Mol Imaging 2008;35:1421-1423.
16. Lloreta J, Domingo P, Pujol R, Arroyo JA, Baixeras N, Matias-Guiu X, et al. Ultrastructural features of highly active antiretroviral therapy-associated partial lipodystrophy. Virchows Arch 2002;441:599-604.
17. McComsey G, Lo R, O'Riordan M, Walker VA, Lebrecht D, Baron E, et al. Effect of reducing the dose of stavudine on body composition, bone density and markers of mitochondrial toxicity in HIV-infected subjects:a randomized, controlled study. Clin Infect Dis 2008;46:1297-1298.
18. Cherry C, lal L, Thompson K, McLean CA, Rose LL, Hernandez J, et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2005;38:263-267.
19. Bleeker-Rovers C, van der Ven A, Zomer B, de Geus-Oei LF, Smits P, Corstens FH, et al. F-18-Fluorodeoxyglucose positron emission tomography for visualization of lipodystrophy in HIV-infected patients. AIDS 2004;18:2430-2432. (Pubitemid 40065912)
20. Hadigan C, Kamin D, Liebau J, Mazza S, Barrow S, Torriani M, et al. Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy. Am J Physiol Endocrinol Metab 2006;290: E289-E298.
21. Behrens G, Boerner A, Weber K, van den Hoff J, Ockenga J, Brabant G, et al. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. J Clin Invest 2002;110:1319-1327.
22. Germinario R, Colby-Germinario S, Camalleri C, Wainberg MA. The long-term effects of anti-retroviral protease inhibitors on sugar transport in L6 cells. J Endocrinol 2003;178:449-456.